Ann: Imugene Licenses Allogeneic CD19 CAR T Cell Therapy, page-95

My 2 cents:

"Imugene will also acquire the lease to a state-of-the art 32,800 sq feet GMP
manufacturing facility in North Carolina, drug material for completion of a Phase 1b clinical
trial and a highly experienced cell therapy and manufacturing team of approximately 50
personnel."

This is part is a cracker anns as well. CHM's CEO Jennifer Chow pointed out several times how hard it is too secure "off the Shelf" cells as there is a huge demand and not much supply. This facility can be used for CHM and ALA as well.

CHM got the CD19 experts, they worked on 4 of the current 6 approved CD19 treatments. I am sure this was a CHM target but it looks like sooner or later IMU will merge with CHM as there are too many synergies developing.

IMO this is a huge deal, Precision like IMU totally beaten down as the market is too dumb to see what's been developed. But the CHM / IMU experts see what's actually being developed. Same as big pharma treated CF33 with ignorance.

Some mentioned the sp of Precision and valued the deal based on that - crappy sp, must be crap. But remember, PH has the ability to see opportunities where the others are blind. The CHM experts have told him to go for it and he jumped on it.

More and more IMU becomes a bigger fish. Those who are just SP-Focussed already have shown their disapproval, but what else can we expect from them.

No idea what the CR price will be, no idea who takes it up. I just hope no retail is involved and no free oppies. We existing sh will definitely buy for less as those short sided holders will sell for much lower than the CR price after the anns.

GLTA